Showing posts with label Imprimis Pharmaceuticals. Show all posts
Showing posts with label Imprimis Pharmaceuticals. Show all posts

Monday, June 17, 2013

Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company Agreement is the first to emerge under exclusive partnership between Imprimis Pharmaceuticals and Professional Compounding Centers of America (PCCA); acquisition allows Imprimis to begin to develop certain innovations created by Ohio-based compounding pha By Imprimis Pharmaceuticals, Inc. Published: Monday, Jun. 17, 2013 - 5:10 am Read more here: http://www.sacbee.com/2013/06/17/5502273/imprimis-pharmaceuticals-inc-acquires.html#storylink=cpy


/PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) today announced it has completed the acquisition of intellectual property (IP) rights related to certain proprietary innovations from the compounding pharmacy operations of Ohio-based Buderer Drug Company. The acquisition allows Imprimis to pursue the commercial development of these proprietary innovations and also provides Imprimis with a right of first refusal on additional Buderer Drug Company intellectual property and drug development opportunities.
Buderer Drug Company, which has served the needs of patients and physicians in Ohio since 1878, is a compounding pharmacy member of PCCA. This IP acquisition is the first to emerge from the Imprimis-PCCA relationship.
"Buderer Drug Company is a leading compounding pharmacy organization in the United States, and we are extremely pleased to announce this asset purchase," said Mark L. Baum, Imprimis CEO. "This new relationship, which could lead to up to three new development programs, is a good example of our plan to begin to leverage our agreement with PCCA into proprietary IP that may ultimately lead to the FDA approval of new medicines to address unmet patient needs. We are in the process of preparing filings with the USPTO related to the acquired assets and intend to communicate with the marketplace with more specificity in the near-term. Ultimately, we intend to develop and commercialize any drug development assets we decide to pursue by utilizing the U.S. Food and Drug Administration (FDA) 505(b)(2) regulatory pathway. The 505(b)(2) pathway has the ability to significantly reduce both cost and duration of the FDA approval process, bringing quality medications more quickly to patients who need them."

continue reading here

Read more here: http://www.sacbee.com/2013/06/17/5502273/imprimis-pharmaceuticals-inc-acquires.html#storylink=cpy

Sunday, June 16, 2013

Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City --- SAN DIEGO, June 14, 2013 Posted at 10:57 AM


  • Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of compounded drug formulations, today announced CEO Mark L. Baum will present at the National Investment Banking Association (NIBA) conference, set for June 17-19 in New York City. The Imprimis presentation is scheduled for June 18(th). About Imprimis Pharmaceuticals, Inc. Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) is a specialty pharmaceutical company focused on the commercial development of compounded drug formulations. Through its exclusive strategic relationship with Professional Compounding Centers of America ... read more

Friday, September 7, 2012

Strategic Agreement Launches Novel Drug Development Model


Professional Compounding Centers of America (PCCA) Invests $4 Million In San Diego-based Imprimis Pharmaceuticals; Agrees to Share Topical Drug-Delivery Knowledge and Technology to Bring New Medicines to Market
SOLANA BEACH, Calif., Sept. 7, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY: OTCQB) today announced a strategic development and investment agreement with Houston-based Professional Compounding Centers of America, Inc. (PCCA). The agreement will allow the companies to develop and share drug-formulation technology, with the goal of creating a new generation of treatments for muscle and joint pain, neuropathic pain and other conditions. PCCA also made a $4 million equity investment in Imprimis in a private transaction.
The agreement will give Imprimis exclusive non-PCCA-member access to PCCA's topical technologies and formulation know-how for delivering drugs directly through the skin. The arrangement is intended to identify development opportunities for new topical medications for new therapeutic applications.
Imprimis' lead drug candidate, Impracor™, a topical non-steroidal anti-inflammatory cream, is expected to enter Phase 3 clinical trials early in 2013. When approved for sale, Impracor would be applied to the site of muscle or joint pain, delivering a clinical dose of medication to the affected area without potential side effects such as stomach irritation or liver problems that have been associated with ingestible, non-steroidal, anti-inflammatory drugs.
The company has also developed Accudel™, a patented topical-delivery platform that can serve as a delivery vehicle for other medications.

To read the remainder of the article, click here.